Evidence map›Paper›PMID 36480201›Full record

ArticleJAMA network open2022

Association of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events.

Alexis F Guédon, Jean-Baptiste De Freminville, Tristan Mirault, Nassim Mohamedi, Bastien Rance, Natalie Fournier, Jean-Louis Paul, Emmanuel Messas, Guillaume Goudot

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Peripheral Artery Disease: Molecular Mechanisms and Novel Therapies.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  10. Lipoprotein(a): Emerging insights and therapeutics.American journal of preventive cardiology · 2024
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Alexis F GuédonVascular Medicine Department, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Cité, Paris, France.
Jean-Baptiste De FreminvilleVascular Medicine Department, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Cité, Paris, France.
Tristan MiraultVascular Medicine Department, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Cité, Paris, France.
Nassim MohamediVascular Medicine Department, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Cité, Paris, France.
Bastien RanceDepartment of Medical Informatics, Georges Pompidou European Hospital, APHP, Université Paris Cité, Paris, France.
Natalie FournierBiology Department, Biochemistry Laboratory, Georges Pompidou European Hospital, APHP, Université Paris Cité, Paris, France.
Jean-Louis PaulBiology Department, Biochemistry Laboratory, Georges Pompidou European Hospital, APHP, Université Paris Cité, Paris, France.
Emmanuel MessasVascular Medicine Department, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Cité, Paris, France.
Guillaume GoudotVascular Medicine Department, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Cité, Paris, France.
Hôpital Européen Georges-Pompidou · FRUniversité Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: High lipoprotein(a) (Lp[a]) levels are involved in the development of cardiovascular events, particularly in myocardial infarction, stroke, and peripheral artery disease. Studies assessing the Lp(a) levels associated with adverse lower-limb events are lacking. Objective: To assess the association between Lp(a) levels and incidence of major adverse limb events in unselected hospitalized patients. Design, Setting, and Participants: This large retrospective monocentric cohort study was conducted from January 1, 2000, to December 31, 2020. Data were derived from the clinical information system of the Hôpital Européen Georges-Pompidou, a Paris-based university hospital. Patients who underwent at least 1 Lp(a) measurement at the center during the study period were included. Patients who had no follow-up data or who had the first Lp(a) measurement after the study outcome had occurred were excluded. Data analyses were performed from May 2021 to January 2022. Main Outcomes and Measures: The primary outcome was the first inpatient major adverse limb event, defined as a major amputation, peripheral endovascular revascularization, or peripheral surgical revascularization, during follow-up. Secondary outcomes included individual components of the primary outcome. Lipoprotein(a) levels were categorized as follows: normal (<50 mg/dL), high (50 to <134 mg/dL), and very high (≥134 mg/dL); to convert Lp(a) values to milligrams per liter, multiply by 0.1. Results: A total of 16 513 patients (median [IQR] age, 58.2 [49.0-66.7] years; 9774 men [59.2%]) were included in the cohort. The median (IQR) Lp(a) level was 24 (10.0-60.0) mg/dL. The 1-year incidence of major adverse limb event was 2.44% in the overall population and 4.54% among patients with very high Lp(a) levels. High (adjusted accelerated failure time [AFT] exponential estimate: 0.43; 95% CI, 0.24-0.78; Benjamini-Hochberg-corrected P = .01) and very high (adjusted AFT exponential estimate: 0.17; 95% CI, 0.07-0.40; Benjamini-Hochberg-corrected P < .001) Lp(a) levels were independently associated with an increased risk of major adverse limb event. Conclusions and Relevance: Results of this study showed that higher Lp(a) levels were independently associated with an increased risk of a major adverse limb event in hospitalized patients. The Lp(a) measurement needs to be taken into account to improve lower-limb vascular risk assessment.

Indexed as

ExtremitiesLipoprotein(a)AgedCohort StudiesHumansMiddle AgedParisRetrospective StudiesLipoprotein(a)

Identifiers

PMID36480201
PMCPMC9856359
OpenAlexW4311937789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.